research chemical raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-01-16 and is reviewed periodically as new material appears.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
| Property | Value | Notes |
|---|---|---|
| Appearance | Off-white to pale yellow solid | Visual description varies with purity and source |
| Solubility | Soluble in DMSO and ethanol; poorly soluble in water | Organic stock solutions are common in research |
| Typical storage | -20 °C, desiccated, protected from light | Avoid repeated freeze-thaw cycles |
| Typical analytical method | LC-MS or HPLC-UV | Reference standards are needed for quantification |
| Molar mass | Approximately 437.9 g/mol | Calculated from the reported free-base formula |
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
AAS performs this analysis by subjecting the sample to an extremely high heat source, breaking the atomic bonds of the substance, leaving free atoms. Radiation in the form of light is then passed through the sample forcing the atoms to jump to a higher energy state. Forensic chemists can test for each element by using a corresponding wavelength of light that forces that element's atoms to a higher energy state during the analysis. For this reason, and due to the destructive nature of this method, AAS is generally used as a confirmatory technique after preliminary tests have indicated the presence of a specific element in the sample. The concentration of the element in the sample is proportional to the amount of light absorbed when compared to a blank sample. AAS is useful in cases of suspected heavy metal poisoning such as with arsenic, lead, mercury, and cadmium. The concentration of the substance in the sample can indicate whether heavy metals were the cause of death.
Due to economic challenges, Latin American area's face disparities regarding income causing high percentage of poverty across the nation. Poverty and socioeconomic status increases mental health issues. Over 90% of Latin American population consist of Catholic and Protestant worshipping churches. The religious and cultural beliefs lead to negative perceptions of mental health which contribute to the stigma of illnesses.
Jung's father was appointed to a more prosperous parish in Laufen when Carl was six months old. Whilst there, tensions between Jung's father and mother had developed. When Jung was three years old, his mother left Laufen for several months of hospitalisation near Basel for some unspecified physical ailment, which he later attributed to problems in their marriage. His father took Carl to be cared for by Emilie Jung's unmarried sister in Basel, but he was later brought back to his father's residence. Carl developed generalised eczema in response. In his memoir, Jung would remark that this parental influence was the "handicap I started off with". After three years living in Laufen, Paul Jung requested a transfer. In 1879, he was called to Klein-Hüningen, next to Basel, where his family lived in a church parsonage. The relocation brought Emilie closer to contact with her family and lifted her melancholy. When Jung was nine, his sister Johanna Gertrud (1884–1935) was born. Known in the family as "Trudi", she later became a secretary to her brother. Jung attended a local village school, and at 10 (or 11) went to Basel Gymnasium, where he was very unhappy. Between ages 17 and 18, Jung became interested in philosophy, in particular in Pythagoras, Heraclitus (a life-long favourite), Empedocles, Plato, Schopenhauer through his The World as Will and Idea, and Kant's Critique of Pure Reason. He also discovered Goethe through Faust and Meister Eckhart, who became life-long favourites.
== History == In the mid-1980s, McDonald's sought to introduce menu items positioned as fresher or lighter options to compete with the Whopper from rival chain Burger King. Reporting on the chain's expansion into fresh vegetables noted that McDonald's had historically resisted placing lettuce and tomato on burgers, fearing the hot meat would wilt the ingredients and make the bun soggy. McDonald's developed a dual-compartment sandwich package that physically separated the hot and cold components. The burger was invented by Wil May, a Lufkin, Texas franchisee. It rolled out nationwide in 1985 as the McDLT. McDonald's use of polystyrene foam packaging became a frequent target of environmental criticism during the late 1980s. Activists often cited the McDLT's large container as a symbol of excessive waste. In late 1990, amid growing public and regulatory pressure, McDonald's announced it would phase out foam packaging. The chain discontinued the McDLT in January 1991, replacing it with the McLean Deluxe, a lower-fat burger that did not use the dual-compartment packaging. McDonald's revisited the "hot and cold" concept in later years with the Big N' Tasty, though it was served in standard cardboard and paper packaging. In 2025, Al Roker said he wished McDonald's would bring back the McDLT.
People with early keratoconus often notice a minor blurring or distortion of their vision, as well as an increased sensitivity to light, so they may visit their clinician seeking corrective lenses for reading or driving. At early stages, the symptoms of keratoconus may be no different from those of any other refractive defect of the eye. As the disease progresses, vision deteriorates, sometimes rapidly due to irregular astigmatism. Visual acuity becomes impaired at all distances, and night vision is often poor. Some individuals have vision in one eye that is markedly worse than the other eye. The disease is often bilateral though asymmetrical. Some develop photophobia (sensitivity to bright light), eye strain from squinting in order to read, or itching in the eye, but there is normally little or no sensation of pain. It may cause luminous objects to appear as cylindrical pipes with the same intensity at all points.
Sources: en.wikipedia.org
phytate), disease and metabolic disorders (e.g. environmental enteric dysfunction), the reproductive cycle, quantity of mineral in diet, chronic mineral deficiency, subject age and homeostatic mechanisms. When results from such studies are available for a mineral, they may serve as a basis for estimations of the human physiological and dietary requirements of the mineral. When tracer is administered with food for the purpose of observing mineral absorption and metabolism, it may be in the form of an intrinsic or extrinsic label. An intrinsic label is isotope that has been introduced into the food during its production, thus enriching the natural mineral content of the food, whereas extrinsic labeling refers to the addition of tracer isotope to the food during the study. Because it is a very time-consuming and expensive approach, intrinsic labeling is not routinely used. Studies comparing measurements of absorption using intrinsic and extrinsic labeling of various foods have generally demonstrated good agreement between the two labeling methods, supporting the hypothesis that extrinsic and natural minerals are handled similarly in the human gastrointestinal tract. Enrichment is quantified from the measurement of isotope ratios, the ratio of the tracer isotope to a reference isotope, by mass spectrometry. Multiple definitions and calculations of enrichment have been adopted by different researchers. Calculations of enrichment become more complex when multiple tracers are used simultaneously. Because enriched isotope preparations are never isotopically pure, i.e.
== Sources == House of Commons Committee on Standards and Privileges (2007), Conduct of Mr George Galloway: Sixth Report of Session 2006–07 (PDF), vol. II, London: The Stationery Office Morley, David (2007a), Gorgeous George: The Life and Adventures of George Galloway, Politico's Publishing, ISBN 9781842751855
=== Types of toxicity === Acute toxicity occurs over hours or a few days. Chronic toxicity results from adult daily intakes greater than 25,000 IU for 6 years or longer and more than 100,000 IU for 6 months or longer.
Like autistic savants, some hyperthymesiacs develop an obsessive fascination with dates. Jill Price, the first documented case, differed notably from mnemonist Solomon Shereshevsky, described by psychologist Alexander Luria. Shereshevsky could deliberately memorise vast amounts of information, whereas Price could recall only autobiographical events and generally performed poorly at memorisation tasks. Hyperthymestic individuals may even have below-average memory for arbitrary information. Another parallel drawn between Price and Shereshevsky is the role of synesthesia. Shereshevsky exemplified time-space synesthesia, and some researchers suggest superior autobiographical memory may be linked to this phenomenon.
1993/2131) Courts and Legal Services Act 1990 (Commencement No. 9) Order 1993 (S.I. 1993/2132) Rules of the Supreme Court (Amendment) 1993 (S.I. 1993/2133) Leasehold Reform, Housing and Urban Development Act 1993 (Commencement and Transitional Provisions No. 1) Order 1993 (S.I. 1993/2134) Edinburgh Assay Office (Amendment) Order 1993 (S.I. 1993/2135) County Court (Amendment No. 2) Rules 1993 (S.I. 1993/2150) Combined Probation Areas (Hertfordshire) Order 1993 (S.I. 1993/2151) Manchester, Liverpool Road (Castlefield Properties Limited) Light Railway Order 1993 (S.I. 1993/2153) East Kent Light Railway Order 1993 (S.I. 1993/2154) Mental Health (Nurses) Amendment Order 1993 (S.I. 1993/2155) Mental Health (Hospital, Guardianship and Consent to Treatment) Amendment Regulations 1993 (S.I. 1993/2156) Leasehold Reform, Housing and Urban Development Act 1993 (Commencement No. 2) (Scotland) Order 1993 (S.I. 1993/2163) Housing (Preservation of Right to Buy) (Scotland) Regulations 1993 (S.I. 1993/2164) Employment Protection (Continuity of Employment) Regulations 1993 (S.I. 1993/2165) Controlled Drugs (Substances Useful for Manufacture) (Intra–Community Trade) Regulations 1993 (S.I. 1993/2166) Tobacco Products (Amendment) Regulations 1993 (S.I. 1993/2167) A45/A452 Trunk Roads (Stonebridge Grade Separation) Order 1993 (S.I. 1993/2168) Education (Further Education Institutions Information) (Wales) Regulations 1993 (S.I. 1993/2169) A45 Trunk Road (Middle Bickenhill to Stonebridge) (De-Trunking) Order 1993 (S.I.
Sources: en.wikipedia.org
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.
The compound is generally handled as light-sensitive and stored cold and dry. Stability in solution depends on solvent, concentration, and storage time. Specific degradation rates are not fully standardized.
Limited water solubility affects formulation for cell and animal studies. Organic co-solvents are often used to dissolve it. Precipitation can confound assay results if not controlled.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.